KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 61,000 shares of KalVista common stock on January 2, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock
Read More

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights   Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sa
Read More

VION Biosciences Names Vince Stoyanov as Chief Strategy and Development Officer

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, today announced Vince Stoyanov as its Chief Strategy and Development Officer. He will lead corporate development, mergers and acquisitions (M&A), and other related corporate functions, bringing both expertise and continued energy to VION at a critical moment in its expansion efforts. With more than 20 ye
Read More

Sapio Sciences Obtient la Certification Hébergeur de Données de Santé (HDS)

BALTIMORE–(BUSINESS WIRE)–Sapio Sciences, la plateforme d’informatique de laboratoire science-aware™, a annoncé aujourd’hui l’obtention de la certification Hébergeur de Données de Santé (HDS), une exigence obligatoire pour les organisations hébergeant des données personnelles de santé en France. L’obtention de la certification HDS souligne la conformité de Sapio Sciences aux normes strictes de sécurité, de confidentialité et de continuité opérationnelle. Cet accomplissement réaffirme l’engage
Read More

Sapio Sciences Achieves Hébergeur de Données de Santé (HDS) Certification

BALTIMORE–(BUSINESS WIRE)–Sapio Sciences, the science-aware™ lab informatics platform, today announced its achievement of the Hébergeur de Données de Santé (HDS) certification, a mandatory requirement for organizations hosting personal health data in France. Achieving HDS certification underscores Sapio Sciences’ compliance with stringent security, privacy, and operational continuity standards. This accomplishment reaffirms the company’s commitment to safeguarding personal health data and adh
Read More

Aicuris Appoints Jacques Dumas as Chief Scientific Officer

WUPPERTAL, Germany–(BUSINESS WIRE)–Aicuris announced today the appointment of Jacques Dumas, Ph.D., as Chief Scientific Officer (CSO), effective January 1, 2025. Dr. Dumas brings over 30 years of experience in pharmaceutical research and development (R&D), with a strong track record of advancing innovative medicines in oncology and infectious diseases from the discovery to launch. In his new role, Dr. Dumas will oversee Aicuris’ R&D efforts, ensuring alignment with the company’s strat
Read More

BOSTON ONCOLOGY ARABIA and SPIMACO Partner to Localize Advanced Oral Oncology Treatments in Saudi Arabia

RIYADH, Saudi Arabia–(BUSINESS WIRE)– #Biotechnology–In a landmark step towards advancing cancer care in the Middle East, BOSTON ONCOLOGY ARABIA and SPIMACO have signed a Memorandum of Understanding (MoU) to localize the production of advanced oral oncology treatments in the Kingdom. Announced at the CPHI Middle East conference, this partnership reflects a shared commitment to improving patient outcomes, fostering local expertise, and contributing to Saudi Arabia’s Vision 2030 goals for healthcare transforma
Read More

Research Using Mirvie RNA Platform Selected for Plenary Session Presentation at the Society for Maternal and Fetal Medicine Annual Meeting

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced the company was selected to present new research demonstrating the ability of the Mirvie RNA platform to predict the risk of severe fetal growth restriction in pregnancy. The abstract, “Prediction of severely small-for-gestational-age infants using a novel cell-free RNA model,” will be presented on Thursday, January 30, 2025 9:1
Read More
Top